These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

192 related items for PubMed ID: 31732528

  • 1. Targeting the Immune Complex-Bound Complement C3d Ligand as a Novel Therapy for Lupus.
    Kulik L, Laskowski J, Renner B, Woolaver R, Zhang L, Lyubchenko T, You Z, Thurman JM, Holers VM.
    J Immunol; 2019 Dec 15; 203(12):3136-3147. PubMed ID: 31732528
    [Abstract] [Full Text] [Related]

  • 2. Epitope mapping using the X-ray crystallographic structure of complement receptor type 2 (CR2)/CD21: identification of a highly inhibitory monoclonal antibody that directly recognizes the CR2-C3d interface.
    Guthridge JM, Young K, Gipson MG, Sarrias MR, Szakonyi G, Chen XS, Malaspina A, Donoghue E, James JA, Lambris JD, Moir SA, Perkins SJ, Holers VM.
    J Immunol; 2001 Nov 15; 167(10):5758-66. PubMed ID: 11698449
    [Abstract] [Full Text] [Related]

  • 3. The benefit of targeted and selective inhibition of the alternative complement pathway for modulating autoimmunity and renal disease in MRL/lpr mice.
    Sekine H, Kinser TT, Qiao F, Martinez E, Paulling E, Ruiz P, Gilkeson GS, Tomlinson S.
    Arthritis Rheum; 2011 Apr 15; 63(4):1076-85. PubMed ID: 21452327
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. IgG4 Autoantibodies Attenuate Systemic Lupus Erythematosus Progression by Suppressing Complement Consumption and Inflammatory Cytokine Production.
    Pan Q, Xiao H, Shi L, He Y, Cai J, Wu J, Li A, Ye L, Yang C, Liu HF.
    Front Immunol; 2020 Apr 15; 11():1047. PubMed ID: 32625200
    [Abstract] [Full Text] [Related]

  • 6. Novel function of complement C3d as an autologous helper T-cell target.
    Knopf PM, Rivera DS, Hai SH, McMurry J, Martin W, De Groot AS.
    Immunol Cell Biol; 2008 Apr 15; 86(3):221-5. PubMed ID: 18180801
    [Abstract] [Full Text] [Related]

  • 7. CR1/CR2 deficiency alters IgG3 autoantibody production and IgA glomerular deposition in the MRL/lpr model of SLE.
    Boackle SA, Culhane KK, Brown JM, Haas M, Bao L, Quigg RJ, Holers VM.
    Autoimmunity; 2004 Mar 15; 37(2):111-23. PubMed ID: 15293881
    [Abstract] [Full Text] [Related]

  • 8. A new mouse anti-mouse complement receptor type 2 and 1 (CR2/CR1) monoclonal antibody as a tool to study receptor involvement in chronic models of immune responses and disease.
    Kulik L, Hewitt FB, Willis VC, Rodriguez R, Tomlinson S, Holers VM.
    Mol Immunol; 2015 Feb 15; 63(2):479-88. PubMed ID: 25457881
    [Abstract] [Full Text] [Related]

  • 9. Human complement receptor 2 (CR2/CD21) as a receptor for DNA: implications for its roles in the immune response and the pathogenesis of systemic lupus erythematosus (SLE).
    Asokan R, Banda NK, Szakonyi G, Chen XS, Holers VM.
    Mol Immunol; 2013 Jan 15; 53(1-2):99-110. PubMed ID: 22885687
    [Abstract] [Full Text] [Related]

  • 10. Role of complement receptor type 2 and endogenous complement in the humoral immune response to conjugates of complement C3d and pneumococcal serotype 14 capsular polysaccharide.
    Mitsuyoshi JK, Hu Y, Test ST.
    Infect Immun; 2005 Nov 15; 73(11):7311-6. PubMed ID: 16239528
    [Abstract] [Full Text] [Related]

  • 11. Structure-guided identification of C3d residues essential for its binding to complement receptor 2 (CD21).
    Clemenza L, Isenman DE.
    J Immunol; 2000 Oct 01; 165(7):3839-48. PubMed ID: 11034390
    [Abstract] [Full Text] [Related]

  • 12. Complement component C3d-antigen complexes can either augment or inhibit B lymphocyte activation and humoral immunity in mice depending on the degree of CD21/CD19 complex engagement.
    Lee Y, Haas KM, Gor DO, Ding X, Karp DR, Greenspan NS, Poe JC, Tedder TF.
    J Immunol; 2005 Dec 15; 175(12):8011-23. PubMed ID: 16339538
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Complement C4 inhibits systemic autoimmunity through a mechanism independent of complement receptors CR1 and CR2.
    Chen Z, Koralov SB, Kelsoe G.
    J Exp Med; 2000 Nov 06; 192(9):1339-52. PubMed ID: 11067882
    [Abstract] [Full Text] [Related]

  • 16. Function of C3 in a humoral response: iC3b/C3dg bound to an immune complex generated with natural antibody and a primary antigen promotes antigen uptake and the expression of co-stimulatory molecules by all B cells, but only stimulates immunoglobulin synthesis by antigen-specific B cells.
    Thornton BP, Vetvicka V, Ross GD.
    Clin Exp Immunol; 1996 Jun 06; 104(3):531-7. PubMed ID: 9099940
    [Abstract] [Full Text] [Related]

  • 17. Decreased expression of the C3b/C4b receptor (CR1) and the C3d receptor (CR2) on B lymphocytes and of CR1 on neutrophils of patients with systemic lupus erythematosus.
    Wilson JG, Ratnoff WD, Schur PH, Fearon DT.
    Arthritis Rheum; 1986 Jun 06; 29(6):739-47. PubMed ID: 2941021
    [Abstract] [Full Text] [Related]

  • 18. Human complement receptor type 2 (CR2/CD21) transgenic mice provide an in vivo model to study immunoregulatory effects of receptor antagonists.
    Kulik L, Chen K, Huber BT, Holers VM.
    Mol Immunol; 2011 Mar 06; 48(6-7):883-94. PubMed ID: 21269698
    [Abstract] [Full Text] [Related]

  • 19. Structural requirements for C3d,g/Epstein-Barr virus receptor (CR2/CD21) ligand binding, internalization, and viral infection.
    Carel JC, Myones BL, Frazier B, Holers VM.
    J Biol Chem; 1990 Jul 25; 265(21):12293-9. PubMed ID: 1695627
    [Abstract] [Full Text] [Related]

  • 20. Complement-mediated activation of the adaptive immune responses: role of C3d in linking the innate and adaptive immunity.
    Toapanta FR, Ross TM.
    Immunol Res; 2006 Jul 25; 36(1-3):197-210. PubMed ID: 17337780
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.